About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

The Company’s current product pipeline includes:

TALICIA - An oral combination therapy for Helicobacter pylori infection, with successful results from a first Phase III study and an ongoing confirmatory Phase III study.

RHB-104 - An oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and a planned pivotal Phase III study for nontuberculous mycobacteria (NTM) infections.

BEKINDA® (RHB-102) - A once-daily oral pill formulation of ondansetron with successful top-line results from a Phase III study for acute gastroenteritis and successful top-line results gastritis and from a Phase II study in IBS-D.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

YELIVA® (ABC294640) - A Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications.

MESUPRON - A Phase II-stage, orally-administered, first-in-class protease inhibitor, targeting pancreatic cancer and inflammatory gastrointestinal diseases. 

RIZAPORT® (RHB-103) - An oral thin-film formulation of rizatriptan for the treatment of acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two EU member states under the European Decentralized Procedure (DCP).

RedHill promotes three gastrointestinal products in the U.S. - Donnatal® - a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; Esomeprazole Strontium Delayed-Release Capsules 49.3 mg - a prescription proton pump inhibitor indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions; and EnteraGam® - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.